Vistagen Therapeutics, Inc. - Common Stock (VTGN)
0.2260
-0.5340 (-70.26%)
NASDAQ· Last Trade: Jun 30th, 6:45 PM EDT
Here are the top movers in Tuesday's session.chartmill.com
Via Chartmill · June 30, 2026
Top movers analysis in the middle of the day on 2026-06-30: top gainers and losers in today's session.chartmill.com
Via Chartmill · June 30, 2026
Traders are paying attention to the gapping stocks in Tuesday's session.chartmill.com
Via Chartmill · June 30, 2026
Vistagen Therapeutics (NASDAQ:VTGN) Faces Muted Market Sentiment as Crucial PALISADE-4 Data Loomschartmill.com
Via Chartmill · June 15, 2026
What's going on in today's pre-market sessionchartmill.com
Via Chartmill · February 13, 2026
Vistagen Therapeutics Inc (NASDAQ:VTGN) Reports Mixed Q3 Results Amid Key Clinical Trial Updateschartmill.com
Via Chartmill · February 12, 2026
Why Did Vistagen Stock Tank 82% Today?stocktwits.com
Via Stocktwits · December 17, 2025

VistaGen (VTGN) Q3 2026 Earnings Call Transcript
Via The Motley Fool · February 12, 2026
Which stocks are moving after the closing bell on Thursday?chartmill.com
Via Chartmill · February 12, 2026
Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via Chartmill · December 22, 2025
The trading volume of these stocks is deviating from the norm in today's session.
Via Chartmill · December 19, 2025
Let's have a look at the stocks with an unusual volume in today's session.
Via Chartmill · December 18, 2025
Via Benzinga · November 17, 2025
Vistagen (VTGN) Q2 2026 Earnings Call Transcript
Via The Motley Fool · November 14, 2025
Via Benzinga · November 12, 2025
Via Benzinga · August 6, 2025

VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025.
Via InvestorPlace · August 13, 2024

Investors looking for millionaire status in the coming years should consider three stocks under $15 that could be worth buying.
Via InvestorPlace · July 26, 2024

VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
Via InvestorPlace · June 12, 2024
